Imedeen Prime Renewal
Imedeen Prime Renewal, NPN 80042200: natural health product licensed in Canada. Medicinal ingredients: Vitis vinifera, Vitamine C, Matricaria chamomilla, Camellia sinensis.
If this product were sold in France
- Legal conditions
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
annexe III, partie B (règlement (UE) 2022/2340). Regulation (EC) No 1925/2006, latest consolidated version, retrieved 21 October 2026, source updated 26 November 2025.
- Legal conditions
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Legal conditions
Glycine max. (L.) Merr.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Vitis vinifera Source : Graine(s) Extraction ratio : 50:1 Dry plant equivalent : 350 mg | 7 mg | Not calculated |
| Vitamine C Source : Ascorbate de sodium | 15 mg | Not calculated |
| Matricaria chamomilla Source : Fleur Extraction ratio : 1.001:1 Dry plant equivalent : 14.51 mg | 14.5 mg | Not calculated |
| Camellia sinensis Source : Feuille Extraction ratio : 5:1 Dry plant equivalent : 77.5 mg Potency : 40 % Polyphenols | 15.5 mg | Not calculated |
| Glycine max Source : Graine(s) Extraction ratio : 25:1 Dry plant equivalent : 2.1875 g Potency : 10 % Isoflavones | 87.5 mg | Not calculated |
| Solanum lycopersicum Source : Chair (fruit) Extraction ratio : 500:1 Dry plant equivalent : 3.625 g Potency : 10 % Lycopene | 7.25 mg | Not calculated |
Non-medicinal ingredients
Talc, pectine, Huile végétale, Amidon de maïs hydrolysé, Polysaccharides de soja, glycérol, Maltodextrine, Shellac, Mono and diglycerides, Caramel, Méthylcellulose, Huile de tournesol, Dioxyde de silicium, Dioxyde de titanium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 4 Comprimé | 1 Tous les jours |
Uses authorised in Canada
Improves firmness of post-menopausal skin. Improves skin quality and suppleness. Vitamin C and Zinc help in connective tissue formation. Zinc helps to maintain healthy skin. Vitamin C and Vitamin E are antioxidants for the maintenance of good health. Provides improved condition, structure and firmness of the skin in post-menopausal women. Improves the appearance and condition of skin in post-menopausal women.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Cautions and Warnings
Pregnant and lactating women should not take any supplements unless recommended by their health care practitioner. Keep out of reach of young children. Consult a health care practitioner if symptoms persist or worsen. Ensure you are up-to-date on mammograms and gynaecological evaluations prior to use. Discontinue use and consult a health care practitioner if you experience breast pain, discomfort and/or tenderness, or if you experience a recurrence of menstruation and/or uterine spotting.
- Contra-Indications
People with a known allergy to seafood, soy or other ingredient in IMEDEEN Prime Renewal should not take this product. IMEDEEN Prime Renewal contains chamomile extract. Do not use if you are allergic to plants of the Asteraceae/Compositae/Daisy family. Consult your healthcare practitioner if you are taking blood thinners. Consult a health care practitioner prior to use if you have a history of hormonal or gynaecological disease, including ovarian cancer, endometriosis, and/or uterine fibroids. Consult a health care practitioner prior to use if you have a liver disorder or develop liver-related symptoms (e.g. abdominal pain, jaundice, dark urine). Consult a health care practitioner prior to use if you are taking hormone replacement therapy (HRT). Do not use if you currently have or previously had breast cancer and/or breast tumours or if you have a predisposition to breast cancer, as indicated by an abnormal mammogram and/or biopsy, or a family member with breast cancer.
Product record
- Licence holder
- Nordic Selfcare Institute
- NPN or DIN-HM
- 80042200
- Status
- Inactive licence
- Licence date
- 10 May 2013
- Revision date
- Not provided
- Form
- Kit
- Route of administration
- Orale
- Application type
- Non traditionnelle
Source
Official Health Canada record, licence 80042200
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Matricaria chamomilla
Read the warning, when it applies and the studies cited
GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Oral
Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000; WHO 1999; Bradley 1992).
Cautions and warnings
When using this product exercise caution if you drive or use machinery as you may experience drowsiness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Health Canada monograph dated 19 December 2025
German Chamomile - Matricaria Chamomilla Topical
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Health Canada monograph dated 31 January 2025
GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Buccal
Route of administration: Buccal (ESCOP 2003; Blumenthal et al. 2000; Bradley 1992)
Cautions and warnings
Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Glycine max
Read the warning, when it applies and the studies cited
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Imedeen Prime Renewal (Nordic Selfcare Institute): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80042200-imedeen-prime-renewal, updated 10 May 2013.